熱門資訊> 正文
Friedreich Ataxia研究结果显示，Lexeo股价下跌24%
2024-07-16 00:03
- Shares of Lexeo Therapeutics (NASDAQ:LXEO) tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy.
- Lexeo said that based on the drug’s observed safety profile and clinical benefits, it plans to explore expedited development for the product, including possible accelerated regulatory approval. The company noted that there are currently no approved treatments for FA cardiomyopathy, according to a statement.
- The company plans to share additional details of the results at a scientific conference in the fall.
- Last year, Biogen’s (BIIB) Skyclarys became the first FDA-approved prescription drug to treat FA, a progressive neuromuscular disease that can also cause cardiomyopathy and diabetes.
- Other companies working on treatments for FA include Larimar Therapeutics (LRMR), PTC Therapeutics (PTCT), Astellas (OTCPK:ALPMF) (OTCPK:ALPMY), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), Prime Medicine (PRME) and Solid Biosciences (SLDB).
More on Lexeo Therapeutics
- Lexeo Therapeutics reports Q1 results
- IPO Roundup: Viking Holdings, RanMarine Technology, and more
- Historical earnings data for Lexeo Therapeutics
- Financial information for Lexeo Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
